Clinical Trial Update: Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing the immunogenicity and safety of NBP608 with Zostavax in healthy adults aged 50 and older has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• NBP608
• Zostavax (Varicella zoster vaccine live)

Snippet

Sponsor: SK Chemicals Co., Ltd. | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED